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Summary Acute haematological toxicity induced by cis-diammine-1,1-cyclobutane dicarboxylate platinum (II)
(carboplatin) and cis-diamminedichloroplatinum (II) (cisplatin) in combination with whole body hyperthermia
(WBH) (2 h at 41.5°C) was examined using a F344 rat model. The thermal enhancement ratios (TERs) of
drug-mediated thrombocytopenia, anaemia and leukopenia were determined from the dose-response curves of
the nadir values of the peripheral platelet, RBC and WBC counts. Carboplatin produced profound depression
of platelet counts which was over three-fold greater than cisplatin (14% vs 51% of the control), while the
decrease in WBC and RBC counts induced by carboplatin did not differ significantly from those observed with
cisplatin. These carboplatin or cisplatin-mediated haematological toxicities were significantly enhanced by
WBH. The depth of decrease in platelet, RBC and WBC counts induced by the maximum tolerated dose
(MTD) of carboplatin (30 mg kg-1) combined with WBH was identical to that induced by the MTD of
carboplatin (70 mg kg-') alone. The TERs of carboplatin-mediated thrombocytopenia, anaemia and leuko-
penia were 2.0, 2.8 and 1.9, respectively. The thermal enhancement of cisplatin mediated haematological
toxicity was similar to that of carboplatin, with TERs of 1.8 for thrombocytopenia, 2.4 for anaemia and 1.9
for leukopenia. These data, demonstrating thermal enhancement of cisplatin or carboplatin-mediated
haematological toxicity, must be taken into account in the clinical application of the combination thereapy of
platinum and WBH.
Hyperthermia has been shown to increase the cytotoxicity of
cisplatin (Hahn, 1979; Barlogie et al., 1980), a
chemotherapeutic agent commonly used for wide spectrum of
human malignancies (Durant, 1980; Zwelling, 1987). At nor-
mal temperature, the clinical use of cisplatin is limited by
severe toxicity to several normal tissues, especially the
kidney, the gastrointestinal tract, and the bone marrow (Rose
et al., 1982; Von Hoff et al., 1979). Simultaneous application
of cisplatin during WBH produces unacceptable renal toxi-
city in humans as well as in experimental animals (Gerard et
al., 1983; Bull, 1984; Mella et al., 1987). Our previous studies
demonstrated that administration of cisplatin combined with
WBH caused a 3-fold increase in renal injury, resulting in a
limited therapeutic gain of this combined modality
(Wondergem et al., 1988a; 1989).
Carboplatin is a new platinum complex with a similar
spectrum of antitumour activity as cisplatin (Wagstaff et al.,
1989). The major advantage ofcarboplatin is that it produces
minimal or no nephrotoxicity. The dose-limiting toxicity of
this analog is myelosuppression, mainly in form of thrombo-
cytopenia (Harrap et al., 1980; Calvert et al., 1982; Wiltshaw,
1985). As observed with cisplatin, the cytotoxicity of carbo-
platin was also enhanced when combined with hyperthermia
in vitro (Cohen & Robbins, 1987; Xu & Alberts, 1988). Our
previous in vivo study showed that WBH significantly
enhanced the antitumour effect induced by carboplatin
against a transplantable fibrosarcoma in rats (Ohno et al.,
1991). The thermal enhancement of carboplatin-mediated
renal injury, was much less than that observed with cisplatin,
resulting in a 3-4-fold increase in therapeutic gain over
cisplatin combined with WBH. These data demonstrated a
potentially useful strategy of using this less nephrotoxic
analog of cisplatin in combination with WBH as an anti-
cancer therapy. Since the major toxicity of the maximum
tolerated dose of carboplatin in combination with WBH
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appeared to be myelosuppression, further detailed studies on
carboplatin-mediated dose-limiting haematological toxicity
under hyperthermic conditions are required for the clinical
application of the combined therapy of carboplatin and
WBH.
The purpose of this study is therefore, to examine the
severity of thrombocytopenia, anaemia and leukopenia
induced by carboplatin or cisplatin in combination with
WBH and to determine and compare the thermal enhance-
ment ratios of those haematological toxicities.
Materials and methods
Animals
Female Fischer 344 rats (Harlan Sprague-Dawley, Inc.,
Indianapolis, Indiana) weighing from 140 to 170 g were used
in all experiments. Rats were fed a diet of standard
laboratory chow, allowed free access to water, and housed
five per cage in a controlled environment with a 12 h light/
dark cycle.
Drugs
Carboplatin was synthesised in-house as described previously
(Baer et al., 1985; Khokhar et al., 1988; Ohno et al., 1991).
Carboplatin and cisplatin (Platinol; Bristol Myers, Syracuse,
NY) were dissolved in 5%-Dextrose in water and in sterile
water, respectively, immediately prior to use. Cisplatin
(1 mgml-') or carboplatin (lOmgml-') was injected by i.v.
bolus through the lateral tail vein of halothane-anesthetised
rats. In rats undergoing WBH, drugs were given simul-
taneously with WBH when the rectal temperature first
reached 41.5°C. Animals not given carboplatin or cisplatin
received the same volume of the drug-reconstituting
vehicle.
WBH
Whole body hyperthermia was induced by immersing
halothane-anesthetised rats into a thermostatically controlled
circulating water bath maintained at 41.5°C by a Haake
Model E heater/circulator, as described previously
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(Wondergem et al., 1988a). An average of 30 min was
required for the rectal temperature to first reach 41.5°C, after
which time the rats were maintained for 2 h at a temperature
of 41.5 ± 0.1°C. Animals not receiving WBH were given
normothermic (37°C) treatment by placement on a circulating
warm water blanket (Blanketrol; Cincinnati, OH) where they
were maintained at a core temperature of 37°C. General
anaesthesia of 1% halothane in pure oxygen as described
previously (Wondergem et al., 1988b) was used for all
treatments.
Haematological toxicity
Determination of peripheral blood cell counts White blood
cell (WBC), red blood cell (RBC) and platelet counts were
determined on a Coulter Counter (model ZM, Coulter Elec-
tronics, Inc., Hialeah, FL), as described previously (Siddik et
al., 1987; Ohno et al., 1991). Briefly, rats were lightly anaes-
thetised with ether and 0.1 ml of blood was obtained from
the ventral tail artery into a heparinised micropipet every 2
days after treatment until day 20 post-treatment and then
finally at day 28 after treatment.
Histopathological study A separate study was performed for
the histopathological examination on the femoral bone mar-
row and the spleen in rats that received the MTDs of carbo-
platin with and without WBH (70 mg kg-' for normothermic
rats and 30 mg kg-' for WBH-treated rats) and the MTDs of
cisplatin with and without WBH (7 mg kg-' for normother-
mic rats and 2 mg kg-' for WBH-treated rats) (Ohno et al.,
1991). These rats were sacrificed on day 3, 5 or 7 after
treatment, and the organs were processed for light micro-
scopic evaluation as previously described (Ohno et al., 1991).
All histopathological examinations were performed by one of
the authors (L.C.S.). Each group consisted of nine rats (three
rats at each time point) in this histopathological study.
Statistics
The estimate of TER was expressed as the ratio of slopes
(Monge & Rofstad, 1989) of the dose-response curves which
was fit to a linear regression (Graphpad Software; ITI press,
Philadelphia, PA), as described previously (Wondergem et
al., 1991).
A two-sided Student's t-test was used to determined statis-
tical significance.
Results
Figure 1 compares the haematological effects of cisplatin and
carboplatin, administered at the maximum tolerated dose
(MTD), with and without WBH, in terms of the time course
of peripheral blood counts (platelets, RBC and WBC) after
treatment. All data are shown as percent of the normother-
mic control.
As shown in Figure la, the most profound effect observed
in this study was a severe carboplatin-mediated throm-
bocytopenia. The MTD of carboplatin, both alone
(70 mg kg-') and combined (30 mg kg-') with WBH, caused
a similar marked decrease in platelet counts to 15% of
control by day 8 post-treatment. In contrast, the MTD of
cisplatin alone (7 mg kg-') produced a much less severe
thrombocytopenia that was characterised by a significantly
higher (P<0.01) nadir of platelet counts of 51% of control,
occurring earlier, by day 6 post-treatment, and the MTD of
cisplatin (2 mgkg-') in combination with WBH resulted in
no significant thrombocytopenia. When a greater than MTD
of cisplatin (3 mg kg-') was administered with WBH, a
similar profile of decrease in platelet counts was observed as
seen with the MTD of cisplatin alone (data not shown). The
50% decrease in platelet count observed on day 2 post-
treatment with both cisplatin and carboplatin in combination
with WBH, can be attributed to the effect of WBH alone, as
previously described (Nakayama & Nakamura, 1984;
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Figure 1 The effect of the MTDs of carboplatin 70 mg kg-
alone ( 0-) and carboplatin 30 mg kg-' combined with WBH
( - ), cisplatin 7 mg kg-' alone (--A --) and cisplatin
2 mg kg-' combined with WBH (--A --) on platelet a, RBC b,
and WBC c, counts as a function of time after treatment. Results
are presented as the mean of three rats and expressed as % of
control. At all time points, the mean value of the 37°C control
group was used as control. Error bars are not shown for clarity
of presentation. Standard errors of the mean (s.e.m.) were less
than 10%.
Wondergem et al., 1991).
The effects of treatment on RBC counts were much less
severe than for platelets (Figure 1b). When comparing the
magnitude of anaemia mediated by the MTD ofcisplatin and
carboplatin, with and without WBH, there appears to be a
trend towards a decrease in RBC counts that is earlier, more
pronounced, and of longer duration for carboplatin under
normothermic and hyperthermic conditions. However, the
nadir of RBC counts for cisplatin with and without WBH
(79 and 72% of control, respectively) and carboplatin with
and without WBH (68 and 60% ofcontrol, respectively) were
not significantly different. WBH alone had no effect on RBC
counts.
A moderate degree of acute leukopenia was also observed
as a result of treatment (Figure lc). The MTDs of carbo-
platin, with and without WBH, showed a similar profile of
WBC counts that was characterised by an almost identical
nadir ofWBC occurring at day 4 post-treatment, followed by
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a pronounced rebound above control levels. In contrast, the
nadirs of leukopenia mediated by the MTDs of cisplatin,
with and without WBH, occurred earlier, at day 2 post-
treatment, and there was less of a rebound effect, especially
for cisplatin combined with WBH. There was no significant
difference in the nadir value of WBC counts when comparing
the MTDs of cisplatin, alone and combined with WBH (45
and 63% ofcontrol, respectively), and carboplatin, alone and
combined with WBH (54 and 59% of control, respectively).
WBC counts were not affected by WBH alone.
In order to generate an estimate of the thermal enhance-
ment ratios for cisplatin and carboplatin-mediated acute
haematological toxicity, in terms of peripheral blood counts,
the approach of Wondergem et al. (1991) was used, and dose
response curves of the mean nadir values of blood counts
were constructed and plotted as a function of cisplatin or
carboplatin dose, with and without WBH (Figures 2, 3 and
4). Data are shown as percent of the 37°C and 41.5°C
control, for normothermic and hyperthermic treatment,
respectively.
The leftward shift of the dose-response curves, in Figures
2, 3 and 4, indicate a thermal enhancement of cisplatin and
carboplatin-mediated haematological toxicity in terms of a
decrease in platelet, RBC, and WBC counts, respectively.
Differences in the haematological effects of carboplatin, or
cisplatin, with and without WBH, were most apparent from
the profile of dose-response curves for the nadir of platelet
counts (Figure 2). Administration of carbonlatin alone at
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Figure 2 Acute platelet depression (expressed as percent of cont-
rol) calculated using the nadir value ofplatelet counts as a function
of carboplatin a, or cisplatin b, dose in rats given drug alone or
drug combined with WBH. Normothermic controls
[9.0 ± 0.5 x 108 ml-' at day 8 post-treatment a, 7.8 + 0.2 x 108 ml-'
at day 6 post-treatment b] and WBH controls [8.7 ± 1.3 x 108 ml- at
day 8 post-treatment a, 10.0 ± 0.3 x 108 ml- at day 8 post-treatment
b] were used for calculation of the platelet depression for the drug
alone and drug combined with WBH, respectively. Points, mean of
three rats per group, except five rats for cisplatin 3 mg kg- ' plus
WBH, and two rats for carboplatin 40 mg kg-' plus WBH; bars,
s.e.m. (shown where they exceed the diameter of the point). One of
three rats given 80 mg kg-' carboplatin alone, one of three rats
given 40 mg kg-' carboplatin plus WBH, and one of six rats given
3 mg kg-' cisplatin plus WBH died at day 10, 4 and 7, respec-
tively.
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Figure 3 Acute RBC depression (expressed as percent control)
calculated using the nadir value of RBC counts as a function of
carboplatin a, or cisplatin b, dose in rats given drug alone or
drug combined with WBH. Normothermic controls [6.7 ± 0.1 x
I09 ml-l at day 12 post-treatment a, 6.9 ± 0.1 x 109 ml ' at day 14
post-treatment b] and WBH controls [6.7 ± 0.1 x I09 ml at day
12 post-treatment a, 6.9 ± 0.2 x 109 ml-' at day 18 post-treatment
b] were used for calculation of the RBC depression for the drug
alone and drug combined with WBH, respectively. Points, mean of
three rats, except five rats for cisplatin 3 mg kg-' plus WBH, and
two rats for carboplatin 80 mg kg-' and carboplatin 40 -mg kg-
plus WBH; bars, s.e.m. (shown where they exceed the diameter of
the point). One of three rats given 80 mg kg-' carboplatin alone,
and one ofthree rats given 40 mg kg-' carboplatin plus WBH, and
one of six rats given 3 mg kg-' cisplatin plus WBH died at day 10,
4 and 7, respectively.
37°C, and in combination with WBH, resulted in similar,
relatively steep dose-response curves, with substantial (50%)
decreases in platelet counts occurring at the lower doses. In
contrast, the dose-response curves for cisplatin-mediated
thrombocytopenia were relatively shallow, both with and
without WBH. When cisplatin was administered under nor-
mothermic conditions, a 50% reduction in platelet counts
occurred only at the MTD, while in combination with WBH,
a significant decrease in platelet counts was observed only
when the cisplatin dose was increased above the MTD to
3mgkg-'.
Dose-response studies of drug-mediated anaemia (Figure
3) also revealed a difference in the haematological effects of
cisplatin compared to carboplatin. The administration of
cisplatin or carboplatin in combination with WBH resulted in
relatively shallow dose-response curves for doses up to and
including the MTD. However, when the dose of carboplatin
was increased by 30% above the MTD to 40mgkg-' com-
bined with WBH, a sharp, additional decrease in RBC counts
down to 28% of control were observed. In contrast, when
the dose ofcisplatin in combination with WBH was increased
by 50% above the MTD, to 3mgkg-', the dose response
curve remained relatively shallow with only a slight further
decrease in RBC counts being observed. Gastrointestinal
bleeding, as determined by the guiac test on bloody diarrhoea
(Ohno et al., 1991), was observed in 3/3 rats receiving car-
boplatin 40 mg kg-' combined with WBH, and may have
contributed to the marked anaemia seen in this group. The
only other rats to exhibit bloody diarrhoea was 1/3 rats
receiving 80 mg kg-I carboplatin at normothermic
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a Table I The slope and correlation coefficienta of the dose-response
curves for carboplatin or cisplatin-mediated haematological toxicity
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Figure 4 Acute WBC depression (expressed as percent ofcontrol)
calculated using the nadir value of WBC counts as a function of
carboplatin a, or cisplatin b, dose in rats given drug alone or drug
combined with WBH. Normothermic controls [7.2 +
0.6 x 106 ml-' at day 4 post-treatment a, 8.2 + 0.6 x 106 ml-' at day
2 post-treatment b] and WBH controls [6.3 ± 0.5 x 106 ml-' at day 4
post-treatment a, 7.2 ± 0.4 x 106 ml-' at day 2 post-treatment b]
were used for calculation of the WBC depression for the drug
alone and drug combined with WBH, respectively. Points, mean of
three rats, except five rats for cisplatin 3 mg kg-' plus WBH, and
two rats for carboplatin 80 mg kg-' and carboplatin 40 mg kg- '
plus WBH; bars, s.e.m. (shown where they exceed the diameter of
the point). One of three rats given 80 mg kg-' carboplatin alone,
one ofthree rats given 40 mg kg- ' carboplatin plus WBH, and one
of six rats given 3 mg kg-' cisplatin plus WBH died at day 10, 4
and 7, respectively.
temperature, which died at day 10 post-treatment with a very
low RBC count (data not included in calculation of RBC
nadir since day 12 was the nadir of RBC counts for all other
carboplatin-treated rats).
As shown in Figure 4, dose response curves of leukopenia
revealed no apparent differences in the magnitude of the
decrease in WBC counts when comparing the effect of cis-
platin and carboplatin, alone and in combination with
WBH.
In an attempt to quantitate the thermal enhancement of
cisplatin and carboplatin-induced haematological toxicity, the
dose-response curves in Figures 2, 3 and 4 were first fit to
linear regression and their respective slopes and correlation
coefficients are summarised in Table I. TERs were then
estimated by taking the ratio of the slope values for drug
alone at 37°C, compared to drug combined with WBH. For
some cases, an exponential function provided a better fit to
the data, however, the estimates for TER were not different
from that obtained by linear regression. As shown in the
summary of TERs in Table II, there was an approximate
2-fold enhancement of carboplatin-mediated thrombocyto-
penia and leukopenia, and a trend towards a slightly greater
2.5-fold increase in anaemia caused by combination with
WBH, and these effects were similar in magnitude to that
resulting from the combination of WBH with cisplatin.
In order to compare the haematological effects of carbo-
platin and cisplatin at the morphological level, histo-
pathological examination was performed on the femoral bone
marrow and the spleen of rats that were sacrificed after
Correlation
Toxicity index Slope coefficient
Thrombocytopenia
Carboplatin alone - 1.209 ± 0.024 - 0.9994
Carboplatin plus WBH - 2.431 ± 0.318 - 0.9834
Cisplatin alone - 6.439± 1.823 - 0.9265
Cisplatin plus WBH - 11.67 ± 2.198 - 0.9507
Anaemia
Carboplatin alone - 0.581 ± 0.116 - 0.9450
Carboplatin plus WBH - 1.651 ± 0.435 - 0.9372
Cisplatin alone - 3.789 ± 0.768 - 0.9584
Cisplatin plus WBH - 8.980 ± 0.879 - 0.9859
Leukopenia
Carboplatin alone - 0.643 ± 0.106 - 0.9612
Carboplatin plus WBH - 1.231 + 0.264 - 0.9571
Cisplatin alone - 7.897 ± 0.306 - 0.9985
Cisplatin plus WBH - 14.80 ± 2.662 - 0.9547
aDose-response curves shown in Figures 2, 3 and 4 were fit to a
linear regression.
Table II Thermal enhancement ratiosa estimated for carboplatin or
cisplatin-mediated haematological toxicities
Toxicity index Carboplatin Cisplatin
Thrombocytopenia 2.0 ± 0.3b 1.8 ± 0.6
Anaemia 2.8 ± 0.9 2.4 ± 0.5
Leukopenia 1.9 ± 0.5 1.9 ± 0.3
aDose-response curves were fit to a linear regression, and the ratio
of the slopes was used for TER estimation. 6Errors are ± s.e.m.
receiving the MTDs of carboplatin 70 mg kg-' alone or
30 mg kg-' combined with WBH, or cisplatin 7 mg kg-'
alone or 2 mg kg-' combined with WBH. The most severe
carboplatin-mediated damage was observed in the femoral
bone marrow examined 5 days after treatment with either
carboplatin alone, or with carboplatin combined with WBH.
When the rats received the MTD of carboplatin, alone or
combined with WBH, moderate general atrophy of the bone
marrow was observed in the femur. This was characterised
by loss of erythropoiesis, elimination of developing myeloid
cells leaving a predominance of mature granulocytes, and
decreased megakaryocytes. On day 7 post-treatment,
recovery of erythropoiesis, myelopoiesis and megakaryocyte
atrophy was observed. The MTD of cisplatin alone caused
only modest hypocellularity in the bone marrow at day 3
post-treatment, which recovered at day 5 post-treatment. The
bone marrow of rats given the MTD of cisplatin combined
with WBH did not differ significantly from that of the con-
trol. In all groups, mild lesions in the spleen were observed at
day 3 or 5 post-treatment, which were characterised by dead
cells in white pulp and decreased extramedullary
haematopoiesis with decreased erythroid and myeloid cells
and megakaryocytes.
Discussion
In this study, we have demonstrated that the simultaneous
administration of cisplatin or carboplatin during WBH can
result in enhancement of cisplatin or carboplatin-mediated
haematological toxicities, such as anaemia, leukopenia, and
thrombocytopenia. Analysis of peripheral blood counts and
femoral bone marrow showed carboplatin to be more
myelotoxic than cisplatin, both with and without WBH.
Thrombocytopenia and bone marrow hypocellularity were
more severe in rats receiving carboplatin, with and without
WBH, than in rats given cisplatin, with and without WBH.
Although severe thrombocytopenia appeared to be dose-
limiting for the combination of carboplatin with WBH,
similar TERs of about 2 were estimated for both carboplatin
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and cisplatin-mediated decrease in platelet counts. Mild to
moderate decreases in WBC and RBC counts were observed
when either cisplatin or carboplatin were administered alone
at 37°C or in combination with WBH, and similar TERs of
approximately 2 and 2.5 were estimated for both drugs, for
leukopenia and anaemia, respectively. Marked anaemia, seen
only with greater than MTD dose of carboplatin, with and
without WBH, was associated with evidence of gastrointes-
tinal bleeding.
The cytotoxicity of platinum compounds is generally
thought to be based on reaction of the platinum molecule
with nucleophilic sites on the DNA (Harder & Rosenberg,
1970). With the combination of cisplatin and hyperthermia
the enhancement of cytotoxicity may be due partly to in-
creased drug uptake in tissues (Bull et al., 1988a; Siddik et
al., 1989), increased DNA cross-link formation (Meyn et al.,
1980), alteration in drug metabolism (Zakris et al., 1987),
and inhibition of DNA repair by heat (Meyn et al., 1979).
Riviere et al. (1990), studying the effects of heat on cisplatin
pharmacokinetics in normal dogs showed in vivo alterations
of different pharmacokinetic parameters. Tissue binding of
free cisplatin was increased at elevated temperatures, leading
to an increase of toxic side effects. Mechanisms for the
WBH-induced enhancement of carboplatin cytotoxicity may
be similar.
Our pharmacological study also showed that the drug
concentration in the femoral bone marrow was increased
when carboplatin or cisplatin was administered during WBH
(Siddik et al., 1990). This increased drug uptake may explain
in part the WBH-induced increase in the haematological
toxicity induced by either carboplatin or cisplatin.
The need to increase the therapeutic gain of the combina-
tion of carboplatin and WBH for clinical application of this
promising combination therapy is essential. In preclinical
studies, the therapeutic index of combined cisplatin plus
WBH was improved by employing a renal protective agent
such as o-(P-hydroxyethyl)-rutoside (venoruton) (Bull et al.,
1988b) or modification of the heat/drug schedule (Baba et al.,
1989). In both studies, WBH enhancement of cisplatin-
mediated normal tissue toxicity was selectively reduced while
the supra-additive antitumour effect was retained. Therefore,
further experiments which explore alterations in heat-drug
sequence and the use of potential normal tissue protective
agents, especially against haematological toxicity are neces-
sary to attempt to reduce or prevent adverse side effects
without interfering with the enhanced antitumour effect of
combined carboplatin plus WBH treatment.
In summary, our studies indicate that thermal enhance-
ment of cisplatin or carboplatin-mediated haematological
toxicity can result from the combination of cisplatin or car-
boplatin with WBH and needs to be taken into consideration
in the clinical application of these combined modalities. Since
thermal enhancement of carboplatin mediated thrombo-
cytopenia appeared to be dose limiting, particular care may
need to be excercised if the clinical protocol combines the
application of this drug and WBH with a second
chemotherapeutic agent, which is also myelosuppressive.
Although the maximum reduction in peripheral blood counts
in this study were not likely to be dose-limiting for combined
cisplatin plus WBH, the TERs for estimated cisplatin-
mediated haematological toxicities were similar to those of
carboplatin. Therefore, if the dose ofcisplatin in combination
with WBH were to escalate with the aid of renal protective
agents or optimal head/drug scheduling, thermal enhance-
ment of cisplatin-induced haematological toxicity may
become an important dose-limiting factor.
The authors thank Miss Gaye Jenkins for her technical assis-
tance.
Abbreviations WBH, whole body hyperthermia; WBC, white blood
cell; RBC, red blood cell; MTD, maximum tolerated dose.
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